Summary
Posterior cortical atrophy (MONDO:0018899) is a disease with 5 cohort genes (18 GWAS associations across 1 studies) and 18 clinical trials. Top therapeutic interventions include gallium ga 68 gozetotide.
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Cohort genes: 5
- GWAS associations: 18
- Phenotypes (HPO): 21
- Clinical trials: 18
Clinical features
Signs & symptoms
Clinical features (HPO)
21 HPO clinical features (Orphanet curated; top 21 by frequency):
| HPO ID | Term | Frequency |
|---|
| HP:0000657 | Oculomotor apraxia | Very frequent (80-99%) |
| HP:0000739 | Anxiety | Very frequent (80-99%) |
| HP:0001251 | Ataxia | Very frequent (80-99%) |
| HP:0001289 | Confusion | Very frequent (80-99%) |
| HP:0002442 | Dyscalculia | Very frequent (80-99%) |
| HP:0010523 | Alexia | Very frequent (80-99%) |
| HP:0010524 | Agnosia | Very frequent (80-99%) |
| HP:0010525 | Finger agnosia | Very frequent (80-99%) |
| HP:0010526 | Dysgraphia | Very frequent (80-99%) |
| HP:0100704 | Cerebral visual impairment | Very frequent (80-99%) |
| HP:0000504 | Abnormality of vision | Frequent (30-79%) |
| HP:0000551 | Color vision defect | Frequent (30-79%) |
| HP:0000613 | Photophobia | Frequent (30-79%) |
| HP:0010522 | Dyslexia | Frequent (30-79%) |
| HP:0030217 | Limb apraxia | Frequent (30-79%) |
| HP:0002354 | Memory impairment | Occasional (5-29%) |
| HP:0002367 | Visual hallucinations | Occasional (5-29%) |
| HP:0002463 | Language impairment | Occasional (5-29%) |
| HP:0002494 | Abnormal rapid eye movement sleep | Occasional (5-29%) |
| HP:0011098 | Speech apraxia | Occasional (5-29%) |
| HP:0030216 | Inertia | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|
| Canonical name | posterior cortical atrophy |
| Mondo ID | MONDO:0018899 |
| Orphanet | 54247 |
| ICD-11 | 377572273 |
| SNOMED CT | 715574002 |
| UMLS | C4275079 |
| MedGen | 909667 |
| GARD | 0018846 |
| Is cancer (heuristic) | no |
Also known as: Benson syndrome · biparietal Alzheimer disease · PCA
Data availability: 18 GWAS associations (1 study).
Disease family
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › dementia › hereditary dementia › posterior cortical atrophy
Related subtypes (14): neuronal intranuclear inclusion disease, hereditary sensory neuropathy-deafness-dementia syndrome, Alzheimer disease 17, Alzheimer disease 18, Huntington disease-like syndrome, frontotemporal dementia with motor neuron disease, frontotemporal dementia, neurodegeneration with brain iron accumulation, PRKAR1B-related neurodegenerative dementia with intermediate filaments, adrenoleukodystrophy, corticobasal syndrome, metachromatic leukodystrophy, autosomal dominant cerebellar ataxia, familial Alzheimer disease
Genetics & variants
GWAS landscape
18 GWAS associations across 1 studies. Top hits map to 12 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|
| rs2075650 | 6e-14 | TOMM40 | ? | 2.03 |
| rs76854344 | 8e-10 | RN7SKP102 - CNTNAP5-DT | ? | 1.9 |
| rs72907046 | 1e-09 | RPSAP72 - TENT5A | ? | 3.2 |
| rs2525776 | 1e-08 | SEMA3C - EIF4EP4 | ? | 3.3 |
| rs6714710 | 1e-06 | ZAP70 | ? | 1.49 |
| rs4965006 | 4e-06 | PUS1 | ? | 1.6 |
| rs2777802 | 6e-06 | ABCA1 | ? | 1.48 |
| rs11637445 | 6e-06 | MAP2K5 | ? | 1.49 |
| rs1014897 | 6e-06 | ANGPT4 | ? | 1.48 |
| rs8038734 | 6e-06 | ARIH1 | ? | 2.14 |
| rs4997950 | 7e-06 | LINC01098, LINC01099 | ? | 1.67 |
| rs10061074 | 7e-06 | HIGD1AP3 - MSX2 | ? | 2.74 |
| rs17125439 | 8e-06 | BCL10-AS1 | ? | 1.51 |
| rs433852 | 8e-06 | FAM83E | ? | 1.68 |
| rs7805053 | 8e-06 | PER3P1 - CPAMD8P1 | ? | 1.53 |
| rs1340425 | 8e-06 | RNU4ATAC8P - LRRIQ3 | ? | 1.63 |
| rs12134133 | 9e-06 | LINC02942 | ? | 1.46 |
| rs10071932 | 9e-06 | GPBP1 - RMEL3 | ? | 1.45 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|
| GCST003452 | Schott JM | 2016 | 293 | 10,547 | Genetic risk factors for the posterior cortical atrophy variant of Alzheimer’s disease. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 1 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 17 |
MAF distribution
| Bucket | Variants |
|---|
| common (>=0.05) | 18 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|
| intron_variant | 11 |
| intergenic_variant | 6 |
| 5_prime_UTR_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|
| rs2075650 | 19 | 44892362 | A>C,G | 0.05 | intron_variant | TOMM40 | 6e-14 | Tier 4: intronic/intergenic |
| rs76854344 | 2 | 123995579 | G>T | 0.05 | intergenic_variant | RN7SKP102 - CNTNAP5-DT | 8e-10 | Tier 4: intronic/intergenic |
| rs72907046 | 6 | 81418166 | A>G | 0.05 | intergenic_variant | RPSAP72 - TENT5A | 1e-09 | Tier 4: intronic/intergenic |
| rs2525776 | 7 | 81272303 | C>T | 0.05 | intergenic_variant | SEMA3C - EIF4EP4 | 1e-08 | Tier 4: intronic/intergenic |
| rs6714710 | 2 | 97728623 | T>A,G | 0.05 | intron_variant | ZAP70 | 1e-06 | Tier 4: intronic/intergenic |
| rs4965006 | 12 | 131934988 | C>T | 0.05 | intron_variant | PUS1 | 4e-06 | Tier 4: intronic/intergenic |
| rs2777802 | 9 | 104807056 | T>A,C,G | 0.05 | intron_variant | ABCA1 | 6e-06 | Tier 4: intronic/intergenic |
| rs11637445 | 15 | 67699268 | G>T | 0.05 | intron_variant | MAP2K5 | 6e-06 | Tier 4: intronic/intergenic |
| rs1014897 | 20 | 914814 | C>G,T | 0.05 | intron_variant | ANGPT4 | 6e-06 | Tier 4: intronic/intergenic |
| rs8038734 | 15 | 72519061 | G>A,C | 0.05 | intron_variant | ARIH1 | 6e-06 | Tier 4: intronic/intergenic |
| rs4997950 | 4 | 177819494 | G>C,T | 0.05 | intron_variant | LINC01098, LINC01099 | 7e-06 | Tier 4: intronic/intergenic |
| rs10061074 | 5 | 174705751 | A>G | 0.05 | intergenic_variant | HIGD1AP3 - MSX2 | 7e-06 | Tier 4: intronic/intergenic |
| rs17125439 | 1 | 85302696 | C>A | 0.05 | intron_variant | BCL10-AS1 | 8e-06 | Tier 4: intronic/intergenic |
| rs433852 | 19 | 48613847 | C>A,T | 0.05 | 5_prime_UTR_variant | FAM83E | 8e-06 | Tier 2: splice/UTR |
| rs7805053 | 7 | 9684086 | C>A,G,T | 0.05 | intron_variant | PER3P1 - CPAMD8P1 | 8e-06 | Tier 4: intronic/intergenic |
| rs1340425 | 1 | 73920165 | C>A,G,T | 0.05 | intergenic_variant | RNU4ATAC8P - LRRIQ3 | 8e-06 | Tier 4: intronic/intergenic |
| rs12134133 | 1 | 207284500 | G>A | 0.05 | intron_variant | LINC02942 | 9e-06 | Tier 4: intronic/intergenic |
| rs10071932 | 5 | 57358044 | T>C | 0.05 | intergenic_variant | GPBP1 - RMEL3 | 9e-06 | Tier 4: intronic/intergenic |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|
| SEMA3C | Orphanet:388 | Hirschsprung disease |
| TOMM40 | Orphanet:1020 | Early-onset autosomal dominant Alzheimer disease |
| TENT5A | Orphanet:216812 | Osteogenesis imperfecta type 3 |
| APOE | Orphanet:329481 | Lipoprotein glomerulopathy |
| APOE | Orphanet:412 | Dysbetalipoproteinemia |
Cohort genes → proteins
5 cohort genes, 5 distinct canonical proteins.
Evidence partition
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|
| SEMA3C | HGNC:10725 | ENSG00000075223 | Q99985 | Semaphorin-3C | gwas |
| TOMM40 | HGNC:18001 | ENSG00000130204 | O96008 | Mitochondrial import receptor subunit TOM40 homolog | gwas |
| TENT5A | HGNC:18345 | ENSG00000112773 | Q96IP4 | Terminal nucleotidyltransferase 5A | gwas |
| CNTNAP5 | HGNC:18748 | ENSG00000155052 | Q8WYK1 | Contactin-associated protein-like 5 | gwas |
| APOE | HGNC:613 | ENSG00000130203 | P02649 | Apolipoprotein E | gwas |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|
| SEMA3C | Semaphorin-3C | Binds to plexin family members and plays an important role in the regulation of developmental processes. |
| TOMM40 | Mitochondrial import receptor subunit TOM40 homolog | Channel-forming protein that forms part of the translocase of the outer mitochondrial membrane (TOM) complex essential for the recognition and translocation of cytosolically synthesized mitochondrial preproteins. |
| TENT5A | Terminal nucleotidyltransferase 5A | Cytoplasmic non-canonical poly(A) RNA polymerase that catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3’-OH terminal group and participates in the cytoplasmic polyadenylation. |
| CNTNAP5 | Contactin-associated protein-like 5 | May play a role in the correct development and proper functioning of the peripheral and central nervous system and be involved in cell adhesion and intercellular communication. |
| APOE | Apolipoprotein E | APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. |
Protein-family classification
Druggable: 2 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.4
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|
| Antibody/Immunoglobulin | 1 | 5.8× | 0.480 |
| Enzyme (other) | 1 | 2.4× | 0.530 |
| Other/Unknown | 3 | 1.1× | 0.608 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|
| SEMA3C | Antibody/Immunoglobulin | yes | | Semap_dom, Ig_sub, Ig-like_dom |
| TOMM40 | Other/Unknown | no | | Porin_dom_sf, Porin_Euk/Tom40, Tom40 |
| TENT5A | Enzyme (other) | yes | 2.7.7.19 | TET5 |
| CNTNAP5 | Other/Unknown | no | | FA58C, EGF, Laminin_G |
| APOE | Other/Unknown | no | | ApoA_E, Apolipoprotein_A1/A4/E |
Expression context
Cohort genes with no expression data: 0.
5 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 5 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|
| calcaneal tendon | 1 |
| mammary duct | 1 |
| synovial joint | 1 |
| mucosa of transverse colon | 1 |
| olfactory bulb | 1 |
| type B pancreatic cell | 1 |
| parotid gland | 1 |
| pericardium | 1 |
| tibia | 1 |
| corpus callosum | 1 |
| cortical plate | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| left adrenal gland | 1 |
| left adrenal gland cortex | 1 |
| right adrenal gland cortex | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|
| SEMA3C | 289 | ubiquitous | marker | mammary duct, synovial joint, calcaneal tendon |
| TOMM40 | 295 | ubiquitous | marker | olfactory bulb, type B pancreatic cell, mucosa of transverse colon |
| TENT5A | 270 | ubiquitous | marker | parotid gland, tibia, pericardium |
| CNTNAP5 | 98 | tissue_specific | marker | male germ line stem cell (sensu Vertebrata) in testis, cortical plate, corpus callosum |
| APOE | 267 | ubiquitous | marker | left adrenal gland, left adrenal gland cortex, right adrenal gland cortex |
Protein interactions among cohort
Intra-cohort edges: 1.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|
| APOE | 6,793 |
| TOMM40 | 3,210 |
| SEMA3C | 1,257 |
| TENT5A | 991 |
| CNTNAP5 | 967 |
Intra-cohort edges
| A | B | Sources |
|---|
| APOE | TOMM40 | string_interaction |
Structural data
PDB: 3 · AlphaFold-only: 2 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|
| APOE | P02649 | 29 |
| TOMM40 | O96008 | 12 |
| TENT5A | Q96IP4 | 2 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|
| SEMA3C | Q99985 | 85.69 |
| CNTNAP5 | Q8WYK1 | 84.06 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 36. Enrichment computed across 5 evidence-associated genes (2 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|
| Chylomicron clearance | 1 | 1142.0× | 0.015 | APOE |
| Chylomicron assembly | 1 | 571.0× | 0.015 | APOE |
| Chylomicron remodeling | 1 | 571.0× | 0.015 | APOE |
| HDL remodeling | 1 | 571.0× | 0.015 | APOE |
| Plasma lipoprotein assembly | 1 | 356.9× | 0.015 | APOE |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 1 | 317.2× | 0.015 | APOE |
| Scavenging by Class A Receptors | 1 | 300.5× | 0.015 | APOE |
| Binding and Uptake of Ligands by Scavenger Receptors | 1 | 271.9× | 0.015 | APOE |
| Plasma lipoprotein remodeling | 1 | 237.9× | 0.015 | APOE |
| Plasma lipoprotein clearance | 1 | 237.9× | 0.015 | APOE |
| NR1H2 and NR1H3-mediated signaling | 1 | 196.9× | 0.015 | APOE |
| Metabolism of fat-soluble vitamins | 1 | 190.3× | 0.015 | APOE |
| PINK1-PRKN Mediated Mitophagy | 1 | 178.4× | 0.015 | TOMM40 |
| Nuclear signaling by ERBB4 | 1 | 173.0× | 0.015 | APOE |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 1 | 154.3× | 0.016 | APOE |
| Signaling by ERBB4 | 1 | 135.9× | 0.016 | APOE |
| Visual phototransduction | 1 | 129.8× | 0.016 | APOE |
| Retinoid metabolism and transport | 1 | 124.1× | 0.016 | APOE |
| Plasma lipoprotein assembly, remodeling, and clearance | 1 | 114.2× | 0.017 | APOE |
| Mitochondrial protein import | 1 | 84.0× | 0.021 | TOMM40 |
| Metabolism of vitamins and cofactors | 1 | 58.3× | 0.029 | APOE |
| Amyloid fiber formation | 1 | 51.4× | 0.030 | APOE |
| Signaling by Nuclear Receptors | 1 | 51.0× | 0.030 | APOE |
| Post-translational protein phosphorylation | 1 | 50.1× | 0.030 | APOE |
| Sensory Perception | 1 | 47.6× | 0.030 | APOE |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 1 | 43.3× | 0.032 | APOE |
| Signaling by Receptor Tyrosine Kinases | 1 | 25.8× | 0.051 | APOE |
| Vesicle-mediated transport | 1 | 17.4× | 0.073 | APOE |
| Transport of small molecules | 1 | 12.6× | 0.097 | APOE |
| RNA Polymerase II Transcription | 1 | 11.3× | 0.104 | APOE |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|
| lipid transport involved in lipid storage | 1 | 3370.4× | 0.006 | APOE |
| maintenance of location in cell | 1 | 3370.4× | 0.006 | APOE |
| intermediate-density lipoprotein particle clearance | 1 | 3370.4× | 0.006 | APOE |
| cardiac endothelial to mesenchymal transition | 1 | 3370.4× | 0.006 | SEMA3C |
| positive regulation of lipid transport across blood-brain barrier | 1 | 3370.4× | 0.006 | APOE |
| regulation of cellular response to very-low-density lipoprotein particle stimulus | 1 | 3370.4× | 0.006 | APOE |
| triglyceride-rich lipoprotein particle clearance | 1 | 1685.2× | 0.007 | APOE |
| regulation of amyloid-beta clearance | 1 | 1685.2× | 0.007 | APOE |
| regulation of amyloid fibril formation | 1 | 1685.2× | 0.007 | APOE |
| pulmonary myocardium development | 1 | 1123.5× | 0.007 | SEMA3C |
| positive regulation of low-density lipoprotein particle receptor catabolic process | 1 | 1123.5× | 0.007 | APOE |
| positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis | 1 | 1123.5× | 0.007 | SEMA3C |
| dichotomous subdivision of terminal units involved in salivary gland branching | 1 | 842.6× | 0.007 | SEMA3C |
| negative regulation of triglyceride metabolic process | 1 | 842.6× | 0.007 | APOE |
| positive regulation of phospholipid efflux | 1 | 842.6× | 0.007 | APOE |
| regulation of behavioral fear response | 1 | 842.6× | 0.007 | APOE |
| very-low-density lipoprotein particle clearance | 1 | 674.1× | 0.007 | APOE |
| acylglycerol homeostasis | 1 | 674.1× | 0.007 | APOE |
| cellular response to lipoprotein particle stimulus | 1 | 674.1× | 0.007 | APOE |
| AMPA glutamate receptor clustering | 1 | 674.1× | 0.007 | APOE |
| NMDA glutamate receptor clustering | 1 | 674.1× | 0.007 | APOE |
| positive regulation of lipoprotein transport | 1 | 674.1× | 0.007 | APOE |
| positive regulation of dendritic spine maintenance | 1 | 674.1× | 0.007 | APOE |
| regulation of amyloid precursor protein catabolic process | 1 | 674.1× | 0.007 | APOE |
| positive regulation of amyloid fibril formation | 1 | 674.1× | 0.007 | APOE |
| chylomicron remnant clearance | 1 | 561.7× | 0.008 | APOE |
| lipoprotein biosynthetic process | 1 | 561.7× | 0.008 | APOE |
| high-density lipoprotein particle clearance | 1 | 481.5× | 0.009 | APOE |
| lipoprotein catabolic process | 1 | 481.5× | 0.009 | APOE |
| negative regulation of cholesterol biosynthetic process | 1 | 481.5× | 0.009 | APOE |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5
Druggability breadth: 1 of 5 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|
| SEMA3C | 0 | 0 |
| TOMM40 | 0 | 0 |
| TENT5A | 0 | 0 |
| CNTNAP5 | 0 | 0 |
| APOE | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|
| TOMM40 | 3 | Binding:3 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|
| TENT5A | 2.7.7.19 | polynucleotide adenylyltransferase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | TENT5A |
| D | Druggable family + AlphaFold only, no drug | 1 | SEMA3C |
| E | Difficult family or no structure, no drug | 3 | TOMM40, CNTNAP5, APOE |
Undrugged target profiles
5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|
| SEMA3C | 0 | — |
| TOMM40 | 3 | — |
| TENT5A | 0 | — |
| CNTNAP5 | 0 | — |
| APOE | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 18.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|
| Not specified | 16 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|
| NCT07052214 | PHASE3 | RECRUITING | PSMA PET Combined With MRI for the Detection of PCa |
| NCT01723553 | PHASE1 | COMPLETED | Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD |
| NCT02740634 | Not specified | ACTIVE_NOT_RECRUITING | Molecular and Structural Imaging in Alzheimer’s Disease: A Longitudinal Study |
| NCT04150198 | Not specified | RECRUITING | MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER’S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY |
| NCT04680130 | Not specified | ENROLLING_BY_INVITATION | Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders |
| NCT04715399 | Not specified | RECRUITING | UPenn Observational Research Repository on Neurodegenerative Disease |
| NCT06820190 | Not specified | RECRUITING | Analgesic Efficacy of Multiple Mid-Transverse Process to Pleura (MTP) Block and PCA in Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion |
| NCT07049341 | Not specified | ENROLLING_BY_INVITATION | Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases |
| NCT07051109 | Not specified | RECRUITING | Dual-chamber Patient-controlled Analgesia for Postoperative Recovery |
| NCT07191327 | Not specified | RECRUITING | Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy |
| NCT07222605 | Not specified | ENROLLING_BY_INVITATION | Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device |
| NCT01095744 | Not specified | COMPLETED | Influence of Age on Amyloid Load in Alzheimer’s Disease and in Atypical Focal Cortical Alzheimer’s Disease |
| NCT02289118 | Not specified | COMPLETED | Tau Imaging in Young Onset Dementia |
| NCT03153371 | Not specified | COMPLETED | Early-onset Alzheimer’s Disease Phenotypes: Neuropsychology and Neural Networks |
| NCT04041089 | Not specified | COMPLETED | Development of the Effectiveness of Rehabilitation Tools for Neurovisual Disorders in Patients With Posterior Cortical Atrophy |
| NCT04929054 | Not specified | UNKNOWN | PCR Based CEUS in BI RADS 4A Nodules |
| NCT05688371 | Not specified | UNKNOWN | Dexmedetomidine Plus Low Dose Morphine Versus Standard Dose of Morphine in PCA in Children . |
| NCT05845281 | Not specified | COMPLETED | Comparison of Erector Spinae Plane Block and Intravenous Patient-controlled Analgesia in Percutaneous Nephrolithotomy |
Drugs tested across these trials (top 30)